1Kimura S,Umeno M,Skoda RC,et al.The human debrisoquine 4-hydroxylase(CYP2D) locus:sequence and identificationof the polymorphic CYP2D6 gene, a related gene and a pseudogene.Am J Hum Genet,1989,45:889
2Steen VM,Andreassen OA,Daly AK,et al.Detection of the poor metabolizer associated CYP2D6 (D) gene detection allele by long-PCR technology.Pharmacogenetics,1995,5:215
3Mamidi RNVS,Satyavageeswaran S,Vakkalanka SVS,et al.Polymorphism of dextrometherphan oxidation in south Indian subjects.Clin Pharmacol Ther,1999,66:193
4Aynacioglu AS,Sachse C,Bozkurt A,et al.Low frequency of active alleles of cytochrome P450 enzyme 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther,1999,66:185
5Bertilsson L.Geographical/Interracial differences in polymorphic drug oxidation:Current state of knownledge of cytochromes P-450(CYP)2D6 and 2C19.Clin Pharmacokinet,1995,29:192
6Dahl ML,Yue QY,Roh HK,et al.Genetic analysis of the CYP2D6 locus in relation to debrisoquine hydroxylation capacity in Korea,Japanese and Chinese subjects.Pharmacogenetics,1995,5:159
7Wrighton SA,Srevens JC,Becker GS.Isolation and characterization of human liver cytochrome P-450 2C19:correlation between 2C19 and S-mephenytoin 4'-hydroxylation.Arch Biochem Biophys,1993,306:240
8De Morais SMF,Wilkinson GR,Blaisdell J.The major genetic defect responsible for the polymorphism of S-mephenytoin in human.J Biol Chem,1994,15:419
9De Morais SMF,Wilkinson GR,Blaisdell J.Identificationof a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese.Mol Pharmacol,1994,46:594
10Cohen LJ,De Vane CL.Clinical implications of antidepressant pharmacokinetics and pharmacogenetics.Ann Pharmacother,1996,30:1471
同被引文献16
1Eichelbaum M, Ingelman-Sundberg M. Pharrnacogenomics and individualized drug therapy[J]. Annu Rev Med, 2006,57:119.
2Schaeffeler E, Schwab M, Eichelbaum M, et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR[J]. Hum Mutat, 2003, 22(6) :476.
3Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6[J]. Int J Clin Pharmacol Res, 7.003,23 ( 1 ) : 31.
4Mamidi RNVS, Satyavageeswaran S, Vakkalanka SVS.et al.Polymorphism of dextromethorphan oxidation in south Indian subjects[J].Clin Pharmacol Ther, 1999,66(2) : 193.
5Aynacioglu AS, Sachse C, Bozkurt A, et aLLow frequency of active alleles of cytochrome P450 enzyme 2C19 and 2D6 in the Turkish population[J].Clin Pharmacol Ther, 1999, 66(2):185.
6Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication[J].Eur J Clin Invest, 2003,33(2) : 17.
7Chen S, Chou WH, Blouin RA, et al.The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism : screening costs and influence on clinical outcomes in psychiatry[J].Clin Pharmacol Ther, 1996,60 (5) : 522.
8Ozdemir V, Naranjo CA, Shulman RW, et al.Determinants of interindividual variability and extent of CYP2D6 and CYP 1A2 inhibition by paroxetine and fluvoxamine invio[J].J Clin Psychopharmacol, 1998,18( 3 ) : 198.
9Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inlaibitors and antidepressants[J].Clin Pharmacol Ther, 2006, 79 (1):103.
10Serretti A, Artioli P. From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes[J]. Psychopharmacology, 2004,174(4) :490.
